Patents Assigned to THIOREDOXIN SYSTEMS AB
  • Patent number: 11801262
    Abstract: Disclosed herein are antibiotic compositions, for example compositions that comprise a metal-containing agent and an organoselenium agent, and uses thereof.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: October 31, 2023
    Assignee: Thioredoxin Systems AB
    Inventors: Arne Holmgren, Jun Lu, Lili Zou
  • Patent number: 11013730
    Abstract: A method for treating a prokaryotic infection in an animal or human by administering a pharmaceutically acceptable composition, comprising administering a source of silver ions and a benzoisoselenazol derivative, e.g., an ebselen derivative.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: May 25, 2021
    Assignee: Thioredoxin Systems AB
    Inventors: Arne Holmgren, Jun Lu
  • Patent number: 10058542
    Abstract: A method for treating a prokaryotic infection in an animal or human by administering a pharmaceutically acceptable composition, comprising administering a source of silver ions and a benzoisoselenazol derivative, e.g., an ebselen derivative.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: August 28, 2018
    Assignee: Thioredoxin Systems AB
    Inventors: Arne Holmgren, Jun Lu
  • Patent number: 8592468
    Abstract: The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors of E. coli TrxR with Ki of 0.14 ?M and 0.46 ?M, respectively. E. coli mutants lacking glutathione reductase or glutathione were much more sensitive to inhibition by ebselen. Since either glutaredoxin or thioredoxin systems are electron donors to ribonucleotide reductase, ebselen targets primarily glutathione and glutaredoxin-negative bacteria, a class which includes major pathogens. Ebselen, and similar compounds are therefore useful as antibacterial agents, even for multiresistant strains.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: November 26, 2013
    Assignee: Thioredoxin Systems AB
    Inventors: Arne Holmgren, Jun Lu, Alexios Vlamis-Gardikas, Rong Zhao, Karuppasamy Kandasamy, Lars Engman, Lars Engstrand, Sven Hoffner
  • Publication number: 20110288130
    Abstract: The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors of E. coli TrxR with Ki of 0.14 ?M and 0.46 ?M, respectively. E. coli mutants lacking glutathione reductase or glutathione were much more sensitive to inhibition by ebselen. Since either glutaredoxin or thioredoxin systems are electron donors to ribonucleotide reductase, ebselen targets primarily glutathione and glutaredoxin-negative bacteria, a class which includes major pathogens. Ebselen, and similar compounds are therefore useful as antibacterial agents, even for multiresistant strains.
    Type: Application
    Filed: March 23, 2011
    Publication date: November 24, 2011
    Applicant: THIOREDOXIN SYSTEMS AB
    Inventors: Arne Holmgren, Jun Lu, Alexios Vlamis-Gardikas, Rong Zhao, K. Kandasamy, Lars Engman, Lars Engstrand, Sven Hoffner
  • Publication number: 20090005422
    Abstract: The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors of E. coli TrxR with Ki of 0.14 ?M and 0.46 ?M, respectively. E. coli mutants lacking glutathione reductase or glutathione were much more sensitive to inhibition by ebselen. Since either glutaredoxin or thioredoxin systems are electron donors to ribonucleotide reductase, ebselen targets primarily glutathione and glutaredoxin-negative bacteria, a class which includes major pathogens. Ebselen, and similar compounds are therefore useful as antibacterial agents, even for multiresistant strains.
    Type: Application
    Filed: May 22, 2007
    Publication date: January 1, 2009
    Applicant: THIOREDOXIN SYSTEMS AB
    Inventors: Arne Holmgren, Jun Lu, Alexios Vlamis-Gardikas, Rong Zhao, K. Kandasamy, Lars Engman, Lars Engstrand, Sven Hoffner